361 results on '"Szegedi, Armin"'
Search Results
2. Translating the HAM-D into the MADRS and vice versa with equipercentile linking
3. What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies
4. OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females
5. Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder
6. Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment
7. Deep Neuromuscular Blockade Improves Laparoscopic Surgical Conditions: A Randomized, Controlled Study
8. Unipolar depressive Störungen : Klinische Psychopharmakotherapie
9. Medikamente zur Behandlung von sexuellen Störungen
10. Antidementiva
11. Medikamente zur Behandlung von Entzugssyndromen und Abhängigkeit
12. Medikamente zur Phasenprophylaxe affektiver Psychosen und zur Behandlung manischer Syndrome
13. Neuroleptika (Antipsychotika)
14. Hypnotika
15. Intoxikationen
16. Pharmakokinetik und Arzneimittelinteraktionen
17. Pharmakotherapie psychiatrischer Akutsituationen
18. Psychopharmaka in Schwangerschaft und Stillzeit
19. Affektive Störungen
20. Psychische Störungen und Verhaltensstörungen durch psychotrope Substanzen
21. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: A pooled analysis
22. Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: A pooled, post hoc analysis from the asenapine development program
23. What does the HAMD mean?
24. Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study
25. Psychopharmaka und Fahrtauglichkeit
26. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression
27. Symptom-Triggered versus Standard Chlormethiazole Treatment of Inpatient Alcohol Withdrawal : Clinical Implications from a Chart Analysis
28. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder
29. Association of VMAT2 gene polymorphisms with alcohol dependence
30. Efficacy and Safety of the Glycine Transporter-1 Inhibitor Org 25935 for the Prevention of Relapse in Alcohol-Dependent Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
31. Medikamente zur Behandlung von Persönlichkeitsstörungen
32. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
33. Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior
34. Placebo controlled continuation treatment with Hypericum extract WS® 5570 after recovery from a mild or moderate depressive episode
35. sj-pdf-3-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
36. sj-pdf-10-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
37. sj-pdf-5-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
38. sj-pdf-9-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
39. sj-pdf-6-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
40. sj-pdf-4-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
41. sj-pdf-2-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
42. sj-pdf-8-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
43. sj-pdf-7-cep-10.1177_0333102420970523 - Supplemental material for Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
44. The Pathophysiology of Schizophrenia
45. The TPH intron 7 A218C polymorphism and TCI dimension scores in alcohol-dependent patients
46. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
47. Unipolar depressive Störungen
48. Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia
49. Efficacy Is Maintained With Long-term Intermittent Use of Ubrogepant for the Acute Treatment of Migraine (111)
50. Ubrogepant Achieves Onset of Pain Relief at 1 Hour for the Acute Treatment of Migraine (1223)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.